Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Depreciation & Amortization (CF) of $4.8 million for Q1 2026, down 0.99% on a QoQ basis from $4.9 million in Q4 2025, and down 0.82% year-over-year from $4.9 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 0.82% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (changed 0.23% YoY) and the FY2025 annual result came in at $19.4 million, changed 0.02% from the prior year.
- Depreciation & Amortization (CF) was $4.8 million for Q1 2026 at Aurinia Pharmaceuticals, down from $4.9 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $5.3 million in Q3 2023 and bottomed at -$6.1 million in Q4 2023.
- A 5-year average of $2.6 million and a median of $4.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) sank 223.16% — and 2024, when it jumped 576.01%.
- Aurinia Pharmaceuticals' Depreciation & Amortization (CF) stood at -$1.9 million in 2022, then sank by 223.16% to -$6.1 million in 2023, then soared by 179.73% to $4.9 million in 2024, then advanced by 0.04% to $4.9 million in 2025, then slipped by 0.99% to $4.8 million in 2026.
- Business Quant data shows AUPH's Depreciation & Amortization (CF) at $4.8 million in Q1 2026, $4.9 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 4.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.82 Mn |
| Mar 31, 2026 | 4.82 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Dec 31, 2023 | -6.10 Mn |